Summit Therapeutics Inc.
NASDAQ:SMMT · NASDAQ Global Market
+$0.19 today
Vol 7.26M · Avg 4.77M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SMMT · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$1.1B of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.40, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 -100.0% | $583.2K -56.4% | $1.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 -100.0% | $583.2K -56.4% | $1.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $537.7M +306.0% | $132.4M -70.9% | $455.3M +958.4% | $43.0M -31.8% | $63.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $556.7M +1051.5% | $48.3M +103.6% | $23.7M +7.3% | $22.1M +26.7% | $17.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.1B +506.3% | $180.5M -62.3% | $478.2M +694.2% | $60.2M -7.5% | $65.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $146.0K +105.6% | $71.0K -54.3% | $155.3K -85.1% | $1.0M +4.9% | $996.1K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$1.1B -540.8% | -$168.5M -142.6% | -$69.5M -34.6% | -$51.6M +19.8% | -$64.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | -8845.1% -4037.3pp | -4807.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$1.1B -506.3% | -$180.5M +62.3% | -$478.2M -701.9% | -$59.6M +6.4% | -$63.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | -10225.4% -5461.1pp | -4764.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $15.5M +15.1% | $13.5M +29.4% | $10.4M +587.6% | $1.5M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $8.7M -47.2% | $16.5M +274.0% | $4.4M +2012.8% | $208.3K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $14.8M +296.7% | $3.7M +190.3% | -$4.1M +25.2% | -$5.5M -209.9% | -$1.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$1.1B -510.7% | -$176.8M +63.4% | -$482.4M -640.2% | -$65.2M +0.5% | -$65.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | -11174.8% -6276.9pp | -4897.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$1.1B -510.7% | -$176.8M +63.4% | -$482.4M -640.2% | -$65.2M +0.5% | -$65.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | -11174.8% -6276.9pp | -4897.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -476.0% | -$0 +67.9% | -$1 -129.4% | -$0 +52.1% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -476.0% | -$0 +67.9% | -$1 -129.4% | -$0 +52.1% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $747.7M +4.7% | $713.9M +15.2% | $619.6M +222.5% | $192.2M +108.3% | $92.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $747.7M +4.1% | $718.5M +16.0% | $619.6M +220.5% | $193.3M +109.6% | $92.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$33.54B
Moderna, Inc.
NASDAQ:MRNA
$24.52B
Royalty Pharma plc
NASDAQ:RPRX
$23.10B
Roivant Sciences Ltd.
NASDAQ:ROIV
$22.44B
Exact Sciences Corporation
EXAS
$20.03B
Ascendis Pharma A/S
NASDAQ:ASND
$14.36B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.20B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.28B
Universal Health Services, Inc.
NYSE:UHS
$8.84B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$213.48M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SMMT generate?
Summit Therapeutics Inc. (SMMT) reported $0.00 of revenue in fiscal 2025.
Is SMMT profitable?
Summit Therapeutics Inc. (SMMT) reported -$1,079,586,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.